We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Moderna said that its COVID-19 vaccine is 93 percent effective six months after the second shot, but that the company is still pressing ahead on developing booster shots. Read More
Full FDA approval for the Pfizer-BioNTech COVID-19 vaccine may be just weeks away, as reports indicate an agency-wide push to meet that goal by Labor Day — if not sooner. Read More
In a late-stage trial, the vaccine proved to be 100 percent effective in preventing moderate and severe disease, and more than 90 percent effective at preventing symptomatic infections. Read More
Emergent BioSolutions, which botched 75 million doses of the Johnson & Johnson (J&J) COVID-19 vaccine, has said publicly for the first time that it has gotten records requests from a slew of federal investigators related to its COVID-19 contracts. Read More
The FDA revised its emergency authorization of Regeneron’s antibody cocktail, REGEN-COV (casirivimab/imdevimab), to include its use for prevention of COVID-19 infection in individuals 12 years and older who have been exposed to the coronavirus and are at high risk of progressing to severe disease. Read More
The FDA is taking an “all-hands-on-deck” approach to swiftly give full approval to the Pfizer-BioNTech COVID-19 vaccine, an agency spokesperson said Friday. Read More
The FDA has given Emergent BioSolutions’ Bayview, Md., facility the green light to restart manufacturing Johnson & Johnson’s (J&J) COVID-19 vaccine — months after new production was put on hold following the discovery of numerous quality issues and cross-contamination with AstraZeneca vaccine doses. Read More
The drugmaker projected that a third dose could yield a 100-fold increase in neutralization of the Delta variant when compared against the two-dose regimen. Read More
A Centers for Disease Control and Prevention (CDC) expert panel has recommended continued use of the single-dose Johnson & Johnson (J&J) COVID-19 vaccine despite reports of Guillain-Barré syndrome (GBS), a neurological illness, in a small number of inoculated individuals. Read More